New eczema drug tested in teens: early safety results
NCT ID NCT07329101
First seen Jan 11, 2026 · Last updated May 20, 2026 · Updated 18 times
Summary
This early-phase study tested a new medicine called VC005 in 11 teenagers aged 12 to 18 with mild to moderate atopic dermatitis (eczema). The main goals were to check safety and how the drug moves through the body. Researchers measured drug levels in the blood over time. This is a first step to see if the drug is safe enough for larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hangzhou First People's Hospital
Hangzhou, Zhejiang, China
Conditions
Explore the condition pages connected to this study.